Innovative Therapies | Transforming Lives

Kineta Secures NIAID Funding to Expand Testing of Immune Modulators

Kineta Secures NIAID Funding to Expand Testing of Immune Modulators

Funding to advance development of compounds that trigger the RIG-I pathway

Seattle, WA, July 12th, 2016 – Kineta, Inc., a biotechnology company focused on the translational development of novel antiviral and immune modulating drugs announced today it has received funding to advance the development of immune modulators.

This National Institute of Allergy and Infectious Disease (NIAID) awarded Kineta with a “direct to phase two” SBIR grant of up to $1.5M over two years. The funds will be used to advance the development of compounds that trigger the RIG-I pathway, activate IRF-3 and induce an antiviral response.

“We are pleased to broaden our longstanding collaboration with the NIAID to advance lead optimization of our novel immune modulating compounds”, said Dr. Shawn Iadonato, Kineta CEO. “These new lead compounds that were identified from Kineta’s AViiD™ screening platform hold tremendous potential to fill significant unmet medical needs in infectious diseases,” Dr. Iadonato added.

Kineta, Inc. is an emerging and sustainable biotech company that fills a void in the biopharmaceutical industry by efficiently advancing therapies from discovery to clinical proof of concept. We actively collaborate with a broad array of private, government and industry partners to advance our innovative research in autoimmune diseases, antivirals and chronic pain. Kineta has established and is expanding on a diverse pipeline of novel life improving therapies that address critical unmet patient needs. For more information on Kineta, Inc. visit our website, www.Kinetabio.com

NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding Kineta’s plans for pre-clinical and clinical studies, regulatory filings, and anticipated drug effects in human subjects. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta’s business which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, and legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and Kineta undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.